Humacyte, Inc. Interest Expense
Humacyte, Inc. (HUMA) reported Interest Expense of $1.82 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-13
- Humacyte, Inc. interest expense for the quarter ending 2024-03-31 was $1.82M, a 6.89% increase year-over-year.
- Humacyte, Inc. interest expense for the quarter ending 2023-12-31 was $1.73M, a 5.37% increase year-over-year.
- Humacyte, Inc. interest expense for the quarter ending 2023-09-30 was $1.46M, a 10.85% decline year-over-year.
- Humacyte, Inc. interest expense for the quarter ending 2023-06-30 was $1.71M, a 14.92% increase year-over-year.
- Humacyte, Inc. interest expense for fiscal 2023 was $6.60M, a 6.44% increase from fiscal 2022.
- Humacyte, Inc. interest expense for fiscal 2022 was $6.20M, a 42.59% increase from fiscal 2021.
- Humacyte, Inc. interest expense for fiscal 2021 was $4.35M, a 97.46% increase from fiscal 2020.
- Humacyte, Inc. interest expense for fiscal 2020 was $2.20M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $1.82M 10-Q · filed 2024-05-13 | $3.54M derived: sum of 2 quarters · filed 2024-05-13 | $5.01M derived: sum of 3 quarters · filed 2024-05-13 | $6.72M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.19M derived: sum of 2 quarters · filed 2024-03-28 | $4.90M derived: sum of 3 quarters · filed 2024-03-28 | $6.60M 10-K · filed 2024-03-28 |
| 2023-09-30 | $1.46M 10-Q · filed 2023-11-09 | $3.17M derived: sum of 2 quarters · filed 2023-11-09 | $4.87M 10-Q · filed 2023-11-09 | $6.51M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-06-30 | $1.71M 10-Q · filed 2023-08-14 | $3.41M 10-Q · filed 2023-08-14 | $5.05M derived: sum of 3 quarters · filed 2024-05-13 | $6.69M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-03-31 | $1.70M 10-Q · filed 2024-05-13 | $3.34M derived: sum of 2 quarters · filed 2024-05-13 | $4.98M derived: sum of 3 quarters · filed 2024-05-13 | $6.47M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.28M derived: sum of 2 quarters · filed 2024-03-28 | $4.77M derived: sum of 3 quarters · filed 2024-03-28 | $6.20M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.64M 10-Q · filed 2023-11-09 | $3.13M derived: sum of 2 quarters · filed 2023-11-09 | $4.56M 10-Q · filed 2023-11-09 | $5.96M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.49M 10-Q · filed 2023-08-14 | $2.92M 10-Q · filed 2023-08-14 | $4.32M derived: sum of 3 quarters · filed 2023-08-14 | $5.52M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.43M 10-Q · filed 2023-05-12 | $2.83M derived: sum of 2 quarters · filed 2023-05-12 | $4.03M derived: sum of 3 quarters · filed 2023-05-12 | $5.25M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $2.60M derived: sum of 2 quarters · filed 2023-03-24 | $3.81M derived: sum of 3 quarters · filed 2023-03-24 | $4.35M 10-K · filed 2023-03-24 |
| 2021-09-30 | $1.20M 10-Q · filed 2022-11-10 | $2.42M derived: sum of 2 quarters · filed 2022-11-10 | $2.95M 10-Q · filed 2022-11-10 | $3.49M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.22M 10-Q · filed 2022-08-12 | $1.75M 10-Q · filed 2022-08-12 | $2.29M derived: sum of 3 quarters · filed 2022-08-12 | $2.84M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $533.00K 10-Q · filed 2022-05-13 | $1.07M derived: sum of 2 quarters · filed 2022-05-13 | $1.62M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $541.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.09M derived: sum of 2 quarters · filed 2022-03-29 | $2.20M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $549.00K 10-Q · filed 2021-11-15 | $1.66M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |